FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152118528> ?p ?o ?g. }

• W3152118528 endingPage "S735" @default.
• W3152118528 startingPage "S735" @default.
• W3152118528 abstract "Background: Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is often diagnosed at an advanced stage. Locally advanced stage III NSCLC represents a highly heterogenous group of patients; treatment poses a challenge, as an accurate evaluation and staging must occur to ensure the selection of an optimal management. Our goal was to characterize a cohort of patients diagnosed with stage III NSCLC, concerning disease characteristics and treatment procedures. Methods: Real-world retrospective cohort study, including patients diagnosed with locally advanced stage III NSCLC between January 1st, 2017 and April 30th, 2018 in a Portuguese Comprehensive Cancer Center (PCCC). Data, collected from medical/administrative records, covered demographics, tumor histology, TNM staging, ECOG performance status, surgical resection, EGFR status, PD-L1 expression, treatment and outcomes. Descriptive statistics analysis was conducted for demographic, clinical and resource utilization data. The Kaplan-Meier method was used for survival analysis. Results: 92 patients were included. Only 18.5% (n = 17) had resectable disease. Before surgery, 29.4% (n = 5) of the patients received neoadjuvant treatment. 81.5% (n = 75) had unresectable disease, and over one third (37.3%) received either concurrent (17.9%; n = 5) or sequential (82.1%; n = 23) chemoradiotherapy (CRT). Tumor histology of patients who received CRT was adenocarcinoma (n = 14) or squamous-cell carcinoma (n = 14). 57.1% (n = 16) of patients had partial response to treatment, 21.4% (n = 6) had stable disease, and disease progression was found in 14.3% (n = 4) of patients. Those who did not receive CRT were mostly treated only with systemic anti-cancer therapy (SACT) (66%; n = 31). The median overall survival of stage III NSCLC was patients was 19.4 months (95%CI 13.9 – NA). Conclusions: Advanced stage III NSCLC is incompatible with a unique schematic treatment approach. Multiple therapeutic strategies are employed as a result of the high variability in tumor extent and nodal involvement. Further research on molecular and immunological characterization is required to better define targeted and effective approaches, with improved outcomes. Legal entity responsible for the study: AstraZeneca Portugal. Funding: AstraZeneca Portugal. Disclosure: F. Bernardo: Full/Part-time employment: AstraZeneca. S. Figueiredo: Full/Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest." @default.
• W3152118528 created "2021-04-13" @default.
• W3152118528 creator A5005112240 @default.
• W3152118528 creator A5022689428 @default.
• W3152118528 creator A5039180839 @default.
• W3152118528 creator A5049173332 @default.
• W3152118528 creator A5050251537 @default.
• W3152118528 creator A5056641693 @default.
• W3152118528 creator A5074370712 @default.
• W3152118528 creator A5075741014 @default.
• W3152118528 date "2021-04-01" @default.
• W3152118528 modified "2023-09-26" @default.
• W3152118528 title "75P Locally advanced, stage III non-small cell lung cancer: A highly heterogenous patient population" @default.
• W3152118528 doi "https://doi.org/10.1016/s1556-0864(21)01917-1" @default.
• W3152118528 hasPublicationYear "2021" @default.
• W3152118528 type Work @default.
• W3152118528 sameAs 3152118528 @default.
• W3152118528 citedByCount "0" @default.
• W3152118528 crossrefType "journal-article" @default.
• W3152118528 hasAuthorship W3152118528A5005112240 @default.
• W3152118528 hasAuthorship W3152118528A5022689428 @default.
• W3152118528 hasAuthorship W3152118528A5039180839 @default.
• W3152118528 hasAuthorship W3152118528A5049173332 @default.
• W3152118528 hasAuthorship W3152118528A5050251537 @default.
• W3152118528 hasAuthorship W3152118528A5056641693 @default.
• W3152118528 hasAuthorship W3152118528A5074370712 @default.
• W3152118528 hasAuthorship W3152118528A5075741014 @default.
• W3152118528 hasBestOaLocation W31521185281 @default.
• W3152118528 hasConcept C121608353 @default.
• W3152118528 hasConcept C126322002 @default.
• W3152118528 hasConcept C141071460 @default.
• W3152118528 hasConcept C143998085 @default.
• W3152118528 hasConcept C146357865 @default.
• W3152118528 hasConcept C151730666 @default.
• W3152118528 hasConcept C167135981 @default.
• W3152118528 hasConcept C195910791 @default.
• W3152118528 hasConcept C2776256026 @default.
• W3152118528 hasConcept C2778424827 @default.
• W3152118528 hasConcept C2781182431 @default.
• W3152118528 hasConcept C2908647359 @default.
• W3152118528 hasConcept C71924100 @default.
• W3152118528 hasConcept C72563966 @default.
• W3152118528 hasConcept C86803240 @default.
• W3152118528 hasConcept C99454951 @default.
• W3152118528 hasConceptScore W3152118528C121608353 @default.
• W3152118528 hasConceptScore W3152118528C126322002 @default.
• W3152118528 hasConceptScore W3152118528C141071460 @default.
• W3152118528 hasConceptScore W3152118528C143998085 @default.
• W3152118528 hasConceptScore W3152118528C146357865 @default.
• W3152118528 hasConceptScore W3152118528C151730666 @default.
• W3152118528 hasConceptScore W3152118528C167135981 @default.
• W3152118528 hasConceptScore W3152118528C195910791 @default.
• W3152118528 hasConceptScore W3152118528C2776256026 @default.
• W3152118528 hasConceptScore W3152118528C2778424827 @default.
• W3152118528 hasConceptScore W3152118528C2781182431 @default.
• W3152118528 hasConceptScore W3152118528C2908647359 @default.
• W3152118528 hasConceptScore W3152118528C71924100 @default.
• W3152118528 hasConceptScore W3152118528C72563966 @default.
• W3152118528 hasConceptScore W3152118528C86803240 @default.
• W3152118528 hasConceptScore W3152118528C99454951 @default.
• W3152118528 hasIssue "4" @default.
• W3152118528 hasLocation W31521185281 @default.
• W3152118528 hasOpenAccess W3152118528 @default.
• W3152118528 hasPrimaryLocation W31521185281 @default.
• W3152118528 hasRelatedWork W1971557041 @default.
• W3152118528 hasRelatedWork W2194997419 @default.
• W3152118528 hasRelatedWork W2277416945 @default.
• W3152118528 hasRelatedWork W2388931413 @default.
• W3152118528 hasRelatedWork W2389744545 @default.
• W3152118528 hasRelatedWork W2400217987 @default.
• W3152118528 hasRelatedWork W2406962104 @default.
• W3152118528 hasRelatedWork W2465910797 @default.
• W3152118528 hasRelatedWork W2801241205 @default.
• W3152118528 hasRelatedWork W4200188553 @default.
• W3152118528 hasVolume "16" @default.
• W3152118528 isParatext "false" @default.
• W3152118528 isRetracted "false" @default.
• W3152118528 magId "3152118528" @default.
• W3152118528 workType "article" @default.